Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gastric Cancer Market Forecast: What Value Will The Market Reach By 2030?
The gastric cancer market has experienced substantial growth in recent years. It is projected to expand from $3.64 billion in 2025 to $4.19 billion in 2026, at a compound annual growth rate (CAGR) of 15.2%. This historical growth can be attributed to factors such as the high prevalence of helicobacter pylori infection, smoking and dietary risk factors, the expansion of chemotherapy usage, the growth of hospital-based oncology care, and the development of surgical oncology.
The gastric cancer market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $7.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.8%. This projected growth during the forecast timeframe is primarily driven by progress in immuno-oncology, an increase in precision diagnostics, the proliferation of cancer screening initiatives, a growing elderly demographic, and the creation of innovative targeted therapies. Key trends anticipated during this period encompass the increasing acceptance of targeted and immunotherapies, a heightened emphasis on early detection and screening, the broadening of personalized cancer treatment strategies, an expanding application of combination therapy protocols, and enhanced multidisciplinary cancer care frameworks.
Get A Free Sample Report With In-Depth Market Insights:
Gastric Cancer Market Development Factors: What’s Supporting Demand?
The increasing prevalence of obesity is anticipated to propel the growth of the gastric cancer market moving forward. Obesity is a medical condition defined by the excessive accumulation of body fat, frequently characterized by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The rise in obesity rates stems from elements such as poor dietary habits, insufficient physical activity, sedentary living, environmental factors, and genetic predispositions. An elevated risk of developing gastric cancer is associated with excess body fat, particularly visceral fat around the abdomen, given that obesity induces chronic inflammation and metabolic disruptions, both implicated in cancer development, which contributes to an increased need for gastric cancer treatment. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that one in eight individuals globally now live with obesity, surpassing 1 billion people. Hence, the escalating obesity rates are driving the gastric cancer market.
Gastric Cancer Market Segmentation And Category Overview
The gastric cancer market covered in this report is segmented –
1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis
3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors
Gastric Cancer Market Trends Powering Strategic Industry Growth
Leading companies in the gastric cancer market are concentrating on the development of technologically advanced solutions, such as companion diagnostic assays, to facilitate personalized treatment. A companion diagnostic assay is a test utilized to identify patients who are most likely to benefit from a specific therapeutic treatment based on the presence of particular biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its VENTANA CLDN18 (43-14A) RxDx Assay. This represents the inaugural immunohistochemistry (IHC) companion diagnostic designed for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. Employing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test advances personalized healthcare and expands treatment options for gastric and GEJ adenocarcinoma.
Gastric Cancer Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Taiho Oncology Inc., Taiho Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biocon Limited, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd
View The Full Gastric Cancer Market Report:
Gastric Cancer Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









